NCT05701553 is a clinical trial of Anti-PD-1/PD-L1 in Hepatocellular Carcinoma, sponsored by Shanghai Zhongshan Hospital.

Who is sponsoring NCT05701553?

NCT05701553 is sponsored by Shanghai Zhongshan Hospital.

What drugs are being tested in NCT05701553?

Interventions in NCT05701553: Anti-PD-1/PD-L1, S-Adenosyl-Methionine.

What condition does NCT05701553 study?

NCT05701553 studies Hepatocellular Carcinoma.

Is NCT05701553 still recruiting?

NCT05701553 is currently status unknown. Last updated 2 February 2023.

Last reviewed 2023-02-02 · How we verify

NCT05701553

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular Carcinoma

Status unknown Last updated 2 February 2023

What this trial tests

trial testing Anti-PD-1/PD-L1 in Hepatocellular Carcinoma in 20 participants. Status unknown.

Timeline

26 January 2023

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	Shanghai Zhongshan Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	20
Start date	26 January 2023
Primary completion	31 December 2025
Estimated completion	31 December 2025
Sites	1 location across China

Drugs / interventions tested

Anti-PD-1/PD-L1 — full drug profile →
S-Adenosyl-Methionine — full drug profile →

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

Shanghai Zhongshan Hospital

Who can join

Adults 18 to 90, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is being done to analyze the safety, tolerability, and efficacy of treatment using combination of SAM and anti-PD-1/PDL1 antibodies for patients with advanced hepatocellular carcinoma.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Tumor metabolic regulators: key drivers of metabolic reprogramming and the promising targets in cancer therapy.
Huang K, Han Y, Chen Y, Shen H, et al · · 2025 · cited 47× · PMID 39789606 · DOI 10.1186/s12943-024-02205-6
Metabolic Signaling in the Tumor Microenvironment.
Clay R, Li K, Jin L. · · 2025 · cited 8× · PMID 39796781 · DOI 10.3390/cancers17010155
Metabolic Checkpoints in CD8<sup>+</sup> T Cells within the Tumor Microenvironment: A Comprehensive Review and Emerging Insights.
Ai J, Du Y, Xue Q, Peng W, et al · · 2026 · PMID 41694600 · DOI 10.7150/ijbs.125206

Verify or expand the search:

Other trials of Anti-PD-1/PD-L1

Trials testing the same drug.

NCT04943679 — Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC · unknown

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Shanghai Zhongshan Hospital trials

Trials by the same sponsor.

NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05701553 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
Last refreshed: 2 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05701553.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing